Pegvisomant is a competitive inhibitor of the hGHR and in clinical trials was >90% effective in normalizing serum IGF1 in patients with acromegaly, despite a >20-fold reduction in hGHR-binding affinity compared to hGH or the hGH-G120K (27). Here, IGF1 is linked to acromegaly.